The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Chatbot Intervention for Reducing HPV Vaccine Hesitancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05959564
Recruitment Status : Completed
First Posted : July 25, 2023
Last Update Posted : August 21, 2023
Sponsor:
Information provided by (Responsible Party):
University of Maryland, College Park

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The goal of this project is to test the efficacy of a chatbot intervention for reducing HPV vaccine hesitancy among African American parents. An online experiment will be conducted to test the effectiveness of the chatbot intervention with African American parents. Results of this project will inform future communication interventions for reducing vaccine hesitancy among African American parents.

Condition or disease Intervention/treatment Phase
Cervical Cancer Anal Cancer Penile Cancer Behavioral: Personalized Chatbot Intervention Behavioral: Non-Personalized Chatbot Intervention Behavioral: No Chatbot Control Not Applicable

Detailed Description:
The goal of this project is to test the efficacy of a chatbot intervention for reducing HPV vaccine hesitancy among African American parents. An online survey-experiment will be conducted. In the survey-experiment, participants will first answer questions related to their attitudes toward childhood vaccines and see a brief CDC message about HPV vaccine. Then they will be directed to interact with a chatbot designed to deliver personalized HPV vaccine messages (tailored to the participant's personality) or a similar chatbot with non-personalized messages. There will also be a control condition where participants will see the brief CDC message about HPV vaccine but will not interact with any chatbot. All participants will answer questions related to their attitudes toward HPV vaccination, intentions to vaccinate their children, as well as other message response measures.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 456 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: A Chatbot Intervention for Reducing HPV Vaccine Hesitancy
Actual Study Start Date : July 26, 2023
Actual Primary Completion Date : August 8, 2023
Actual Study Completion Date : August 8, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vaccines

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Personalized Chatbot Condition
After reading a standard CDC HPV vaccine message, participants will interact with a chatbot designed to deliver personalized HPV vaccine messages (i.e., tailored to their personalities).
 Behavioral: Personalized Chatbot Intervention
In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are tailored to their personalities.
Experimental: Non-Personalized Chatbot Condition
After reading a standard CDC HPV vaccine message, participants will interact with a chatbot designed to deliver HPV vaccine messages, which are not tailored to their personalities.
 Behavioral: Non-Personalized Chatbot Intervention
In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are not tailored to their personalities.
Active Comparator: No Chatbot Control Condition
Participants will read a standard CDC HPV vaccine message without interacting with any chatbot that delivers additional messages.
 Behavioral: No Chatbot Control
In this intervention, participants will see a standard CDC HPV vaccine message only and will not interact with any chatbot.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Attitudes toward HPV vaccination [ Time Frame: Immediately after the intervention ]
    Participants' attitudes toward HPV vaccination will be measured by seven questions such as ""The HPV vaccine is beneficial for adolescents."

  2. Intentions toward HPV vaccination [ Time Frame: Immediately after the intervention ]
    Participants' intentions toward vaccinating their children against HPV will be measured by three questions such as "I am likely to get my child/children the HPV vaccine."


Secondary Outcome Measures :
  1. Ratings of the Chatbot [ Time Frame: Immediately after the intervention ]
    Participants in the chatbot conditions will rate the chatbot on a number of characteristics such as engagingness, relevance, and trustworthiness.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18 years or older
  • Self-identify as Black or African American
  • Parents of children under 18 years old
  • Access to computer/laptop/mobile device and the Internet

Exclusion Criteria:

  • Under 18 years
  • Does not self-identify as Black or African American
  • Not a parent of at least a child under 18 years old
  • No access to computer/laptop/mobile device or the Internet
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05959564


Locations
Layout table for location information
United States, Maryland
University of Maryland, College Park (Online Survey-Experiment)
College Park, Maryland, United States, 20742
Sponsors and Collaborators
University of Maryland, College Park
Investigators
Layout table for investigator information
Principal Investigator: Xiaoli Nan University of Maryland, College Park
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University of Maryland, College Park
ClinicalTrials.gov Identifier: NCT05959564    
Other Study ID Numbers: 1960782-1
First Posted: July 25, 2023    Key Record Dates
Last Update Posted: August 21, 2023
Last Verified: August 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: We will share anonymized data on data repositories such as the Open Science Framework.
Supporting Materials: Study Protocol
Time Frame: After the study is published, for 5 years.
Access Criteria: All information is open to the public.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anus Neoplasms
Penile Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urogenital Diseases
Genital Diseases
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
 Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Anus Diseases
Rectal Diseases
Genital Neoplasms, Male
Genital Diseases, Male
Penile Diseases
Male Urogenital Diseases